紫杉醇联合蒽环类药物治疗晚期乳腺癌的临床疗效观察

Clinical Efficacy of Paclitaxel Combined with Anthracycline in the Treatment of Advanced Breast Cancer

目的分析紫杉醇联合蒽环类药物治疗晚期乳腺癌的临床效果,观察紫杉醇联合蒽环类药物治疗晚期乳腺癌的安全性。方法选取我院肿瘤内科2016年1月至2018年1月收治的晚期乳腺癌患者55例,将患者随机分为对照组和观察组,观察组患者采用紫杉醇联合蒽环类药物方案治疗,对照组采用传统的CAF方案治疗,观察两组患者临床疗效和不良反应发生情况。结果观察组患者完全缓解7例,部分缓解14例,进展3例,稳定1例,总有效率为84.0%;对照组患者完全缓解7例,部分缓解10例,进展7例,稳定6例,总有效率为56.7%;两组患者总有效率比较差异有统计学意义(P<0.05)。观察组患者神经毒性和肌肉关节疼痛与对照组有显著性差异,差异有统计学意义(P<0.05);两组患者在血细胞下降、血小板下降、恶心、贫血、脱发、肝功能异常和过敏反应的差异无统计学意义(P>0.05)。结论紫杉醇联合蒽环类药物方案治疗晚期乳腺癌患者的临床效果好,不良反应较轻,需要积极预防并发症的发生,值得在临床上广泛推广。

0bjective To analyze the clinical effect of paclitaxel combined with anthracycline in the treatment of advanced breast cancer and to observe the safety of paclitaxel combined with anthracycline in the treatment of advanced breast cancer. Methods 55 cases of advanced breast cancer admitted from January 2016 to January 2018 in our hospital were randomly divided into control group and observation group. Patients in observation group were treated with paclitaxel combined with anthracycline and control group Traditional CAF treatment was used to observe the clinical efficacy and adverse reactions in both groups. Results The patients in the observation group were completely relieved in 7 cases, partially relieved in 14 cases, advanced in 3 cases and stable in 1 case, with a total effective rate of 84.0%. In the control group, 7 were completely relieved, 10 were partially relieved, 7 were progressive, 6 were stable, The total effective rate was 56.7%. There was significant difference between the two groups in the total effective rate （P〈0.05）. Neurological toxicity and muscle and joint pain in the observation group were significantly different from those in the control group （P〈0.05）. There were significant differences in the blood cell count, thrombocytopenia, nausea, anemia, hair loss, liver dysfunction and anaphylaxis between the two groups The difference was not statistically significant （P〉0.05）. Conclusion Paclitaxel combined anthracycline regimen in patients with advanced breast cancer clinical effect is good, less adverse reactions, the need to actively prevent the occurrence of complications, it is worth widely disseminated in the clinic.